Search research articles
Contact Us
Filters
Showing results (81-90 of 97) with videos related to
Page
of 10
Sort By:
Communications Medicine
|
April 24, 2025
Effect of heterologous intranasal iNCOVACC<sup>®</sup> vaccination as a booster to two-dose intramuscular Covid-19 vaccination series: a randomized phase 3 clinical trial
Venkateshwar Rao Akula, Amit Suresh Bhate, Chandrasekhar S Gillurkar, et al.
Clinical and Translational Medicine
|
April 9, 2025
Severe SARS-CoV-2 infection in diabetes was rescued in mice supplemented with metformin and/or αKG, and patients taking metformin, via HIF1α-IFN axis
Garima Joshi, Garima Verma, Simrandeep Kaur, et al.
Clinical Nuclear Medicine
|
November 8, 2017
Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy
Akshima Sharma, Anant Mohan, Ashu Seith Bhalla, et al.
Advanced Biology
|
October 3, 2023
Biocompatible Human Placental Extracellular Matrix Derived Hydrogels
Sunil Gujjar, Anurag Tyagi, Saloni Sainger, et al.
NPJ Vaccines
|
January 3, 2024
A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation
Akshay Binayke, Aymaan Zaheer, Siddhesh Vishwakarma, et al.
IJID Regions
|
January 19, 2026
Corrigendum to 'Immunogenicity and safety of Biological E's CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised phase III clinical study' [IJID Regions, volume 17 (2025) 100786]
Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, et al.
IJID Regions
|
November 17, 2025
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A prospective double-blind randomized phase III clinical study
Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, et al.
Journal of Medical Virology
|
August 22, 2024
Understanding the landscape of the SARS-CoV-2-specific T cells post-omicron surge
Akshay Binayke, Aymaan Zaheer, Siddhesh Vishwakarma, et al.
Communications Biology
|
September 13, 2023
Omicron sub-lineage BA.5 infection results in attenuated pathology in hACE2 transgenic mice
Zaigham Abbas Rizvi, Jyotsna Dandotiya, Srikanth Sadhu, et al.
European Journal of Medical Research
|
December 4, 2023
Adhatoda vasica and Tinospora cordifolia extracts ameliorate clinical and molecular markers in mild COVID-19 patients: a randomized open-label three-armed study
Mukta Verma, Neha Rawat, Ritu Rani, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 97) with videos related to
Sort By:
Page
of 10
Communications Medicine
|
April 24, 2025
Effect of heterologous intranasal iNCOVACC<sup>®</sup> vaccination as a booster to two-dose intramuscular Covid-19 vaccination series: a randomized phase 3 clinical trial
Venkateshwar Rao Akula, Amit Suresh Bhate, Chandrasekhar S Gillurkar, et al.
Clinical and Translational Medicine
|
April 9, 2025
Severe SARS-CoV-2 infection in diabetes was rescued in mice supplemented with metformin and/or αKG, and patients taking metformin, via HIF1α-IFN axis
Garima Joshi, Garima Verma, Simrandeep Kaur, et al.
Clinical Nuclear Medicine
|
November 8, 2017
Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy
Akshima Sharma, Anant Mohan, Ashu Seith Bhalla, et al.
Advanced Biology
|
October 3, 2023
Biocompatible Human Placental Extracellular Matrix Derived Hydrogels
Sunil Gujjar, Anurag Tyagi, Saloni Sainger, et al.
NPJ Vaccines
|
January 3, 2024
A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation
Akshay Binayke, Aymaan Zaheer, Siddhesh Vishwakarma, et al.
IJID Regions
|
January 19, 2026
Corrigendum to 'Immunogenicity and safety of Biological E's CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised phase III clinical study' [IJID Regions, volume 17 (2025) 100786]
Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, et al.
IJID Regions
|
November 17, 2025
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A prospective double-blind randomized phase III clinical study
Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, et al.
Journal of Medical Virology
|
August 22, 2024
Understanding the landscape of the SARS-CoV-2-specific T cells post-omicron surge
Akshay Binayke, Aymaan Zaheer, Siddhesh Vishwakarma, et al.
Communications Biology
|
September 13, 2023
Omicron sub-lineage BA.5 infection results in attenuated pathology in hACE2 transgenic mice
Zaigham Abbas Rizvi, Jyotsna Dandotiya, Srikanth Sadhu, et al.
European Journal of Medical Research
|
December 4, 2023
Adhatoda vasica and Tinospora cordifolia extracts ameliorate clinical and molecular markers in mild COVID-19 patients: a randomized open-label three-armed study
Mukta Verma, Neha Rawat, Ritu Rani, et al.
Page
of 10